Skip to main content
. Author manuscript; available in PMC: 2014 Jan 14.
Published in final edited form as: Cancer Cell. 2013 Jan 3;23(1):23–34. doi: 10.1016/j.ccr.2012.11.017

Figure 3. Itraconazole combines with cyclopamine to inhibit GDC-0449-resistant SMO function.

Figure 3

(A) Relative 8×-GLI-luciferase expression in SHHN-stimulated Smo−/− MEFs expressing SMOWT or SMOD477G, treated with GDC-0449, itraconazole, or both. (B) Effect of KAAD-cyclopamine 100 nM, itraconazole 2 μM, or both on SHHN-stimulated 8×-GLI-luciferase expression in Smo−/− MEFs expressing SMOD477G. (C) Dose-response curves of KAAD-cyclopamine for SHHN activated signaling in Smo−/− MEFs expressing SMOD477G, in the presence or absence of itraconazole. Data represent mean of triplicates ± SD. See also